AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00935402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
Study NCT00935402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
Study NCT00942591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b
Study NCT00942591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b
Study NCT00942591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Vehicle
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Study NCT03920228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: PTX-022 QTORIN
Study NCT03920228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical
Study NCT03920228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical
Study NCT06723314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Subperiosteal Tunnel Access vista
Description: CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
Study NCT06723314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Subperiosteal Tunnel Access vista
Description: CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
Study NCT00385580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
Study NCT03690479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ball Tip Probe
Description: Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
Study NCT00385580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
Study NCT02945384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Connections: Strong Families, Strong Brains
Description: Dual-generation intervention
Study NCT04468256 — intervention group
Intervention type: OTHER
Intervention: COVID-19 experience surveys
Description: Serial online surveys recording experiences of the COVID-19 pandemic.
Study NCT01766674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis spinal strengthening exercises
Description: Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
Study NCT03387033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation response and virtual reality (VR) session
Description: A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
Study NCT01928446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
Study NCT01472198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Study NCT01472198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Study NCT01472198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Study NCT01472198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match simtuzumab
Description: Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Study NCT00969475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis fractional carbon dioxide laser
Description: intra-operative laser resurfacing at time of wound closure
Study NCT00003508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT04575168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 Test
Description: A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
Study NCT01928446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be administered for the duration of follow-up (1 year).
Study NCT01834885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 via inhaler twice a day
Study NCT01834885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: fluticasone/slameterol via inhaler twice a day
Study NCT04046042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Virtual reality exercise performed during the first two hours of the hemodialysis session
Study NCT04046042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise during the last two hours of the hemodialysis session
Description: Virtual reality exercise performed during the last two hours of the hemodialysis session
Study NCT04295395 — intervention group
Intervention type: DEVICE
Intervention: NONIN SenSmart model X-100 near- infrared spectrometer
Description: for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
Study NCT03625401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-35 60mg group
Description: AD-35 60mg QD
Study NCT03625401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo: 3 placebo of AD-35 30mg tablets
Study NCT04366479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multistage Fitness Test
Description: Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
Study NCT02300025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: single oral 10-mg dose of cobimetinib
Study NCT04274452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod
Study NCT04274452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study NCT01126515 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
Study NCT01126515 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography Angiography
Description: Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
Study NCT03687125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Participants received tinostamustine IV injection.
Study NCT03687125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Undergo autologous stem cell transplant
Study NCT01982487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Description: Given SC
Study NCT01982487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 inhibitor INCB024360
Description: Given PO
Study NCT01982487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01982487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02022007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study
Study NCT02022007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study
Study NCT02022007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin-Metformin XR
Description: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study
Study NCT04248855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAN-101
Description: Intravenous (IV) infusion
Study NCT04248855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) infusion
Study NCT00385541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA
Description: Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
Study NCT00385541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone PCA
Description: hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
Study NCT00902135 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
Study NCT00902135 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
Study NCT00902135 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b (Betaferon)
Study NCT04272021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: standard therapy for ADHD
Study NCT03939169 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Installation of a naso-gastric feeding tube
Description: Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
Study NCT03734965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AWAKEN INTUBATION
Description: Intubation
Study NCT03734965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWAKEN INTUBATION
Description: Intubation
Study NCT02725970 — intervention group
Intervention type: OTHER
Intervention: survey
Description: Cross-sectional survey
Study NCT02785640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hourly prompts to stand delivered by Microsoft Outlook
Description: Prompt group
Study NCT03297515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Madeos
Description: Arm 1: Omega 3
Study NCT03297515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 2 : Placebo
Study NCT00652158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8054
Description: 10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days
Study NCT02489955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Study NCT02489955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Study NCT02489955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colomycin
Study NCT01168193 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT03852563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol)
Description: Product is applied to one hemiface.
Study NCT03852563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol)
Description: Product is applied to one hemiface.
Study NCT03852563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study NCT03852563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI
Description: non contrast heart MRI at baseline and after 1 year of therapy
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: non contrast heart MRI at baseline and after 1 year of therapy
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography with strain
Description: echocardiography at baseline and after 1 year of therapy
Study NCT02320357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment by clopidogrel
Description: Peripheral blood will be obtained during the study
Study NCT02456909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia pump with Cues
Description: The end of the lockout period will be cued via the PCA pump
Study NCT02456909 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-Controlled Analgesia pump without Cues
Description: The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
Study NCT02456909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
Study NCT02456909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
Study NCT04604639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NEWS2 score
Description: Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
Study NCT00929708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Dry powder for inhalation, o.d., 4 weeks
Study NCT00929708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Dry powder for inhalation, b.i.d., 4 weeks
Study NCT00929708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for inhalation, b.i.d., 4 weeks
Study NCT00721058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CT-scan
Description: A pre-operative CT-scan will be made
Study NCT01687309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2586184 800mg single and repeat dose
Description: GSK2586184 800mg single dose and then twice daily dosing for 13 days
Study NCT01687309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-to-match GSK2586184
Description: Placebo-to-match GSK2586184
Study NCT01687309 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GSK2586184 single dose taken with food
Description: GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
Study NCT01687309 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GSK2586184 single dose taken without food
Description: GSK2586184 single dose taken in a fasted state
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: echocardiography with strain
Description: echocardiography at baseline and after 1 year of therapy
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory tests
Description: drawing blood from dialysis machine
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: drawing blood from dialysis machine
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Body composition monitoring
Description: Measurement with BCM (Fresenius) machine
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body composition monitoring
Description: Measurement with BCM (Fresenius) machine
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasound
Description: ultrasound
Study NCT03182699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: ultrasound
Study NCT01169714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg PF-04995274
Description: 0.1 mg PF-04995274, qd, for 14 days or placebo
Study NCT01169714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg PF-04995274
Description: 1 mg PF-04995274, qd, for 14 days or placebo
Study NCT01169714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-04995274
Description: 10 mg PF-04995274, qd, for 14 days or placebo
Study NCT01169714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg PF-04995274
Description: 15 mg PF-04995274, qd, for 14 days or placebo
Study NCT01169714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg PF-04995274
Description: 1.0 mg PF-04995274, qd, for 14 days or placebo
Study NCT02758353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Community distribution of SP
Description: SP delivered at both the community and facility level by trained CBHVs in three LGAs.
Study NCT02465281 — intervention group
Intervention type: OTHER
Intervention: Device: 3T scanner with MRI-compatible robot
Study NCT02422602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto
Description: Taking conventional charge
Study NCT02422602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Personalized information intervention